Skylar Jeremias


More Patients With Advanced Tumors May Benefit From Genomic Profiling Testing Than Previously Thought

September 21, 2021

Polymerase chain reaction–based comprehensive genomic profiling testing provided useful information for more than 94% of samples, including 81% of samples that normally would not have been tested, suggesting that more patients may benefit from CGP testing than anticipated.

FDA Approves First Biosimilar for Lucentis

September 20, 2021

Byooviz becomes the first FDA-approved ophthalmology biosimilar and the first FDA-approved biosimilar referencing Lucentis (ranibizumab), according to a statement from developers Samsung Bioepis and Biogen.

Study Detects Biomarkers for Poor Prognosis in Premenopausal Patients With HR+/HER2– Advanced Breast Cancer

September 18, 2021

Investigators confirmed prognostic biomarkers for premenopausal patients with hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer, which could potentially be used to inform treatment decisions.

MS Disability, Symptoms Are Worse in Non-White Patients, Study Finds

September 16, 2021

Non-white patients with multiple sclerosis (MS), particularly African American and Hispanic American patients, were found to experience a higher level of overall disability and more severe symptoms, highlighting current disparities in this disease.

The Role of Liquid Biopsy in Determining Prognosis, Treatment in Surgical Oncology

September 15, 2021

A literature review detailed the multitude of ways that liquid biopsy can be used to aid the treatment of patients with cancer, including aiding in screening, recurrence surveillance, genomic profiling, and therapeutic decision-making.

Prognostic Biomarkers Identified for Pancreatic Ductal Adenocarcinoma Using Whole Genome Sequencing

September 11, 2021

Investigators identified 5 mutated genes that could serve as biomarkers for disease prognosis and clinical outcomes associated with pancreatic ductal adenocarcinoma, a common cancer with a high mortality rate and poor prognosis.

Study: COVID-19 Barriers Halted, Delayed Research on MS Rehabilitation, Quality of Life

September 08, 2021

In a survey, researchers indicated that the COVID-19 pandemic has placed extra barriers, including a lack of accessibility to patients and competing responsibilities, that have resulted in halts or delays to research on multiple sclerosis (MS) rehabilitation and quality of life.